SKF-81,297
Synthetic drug, a stimulant
From Wikipedia, the free encyclopedia
SKF-81,297 is a dopamine D1-like receptor agonist and stimulant-like drug of the 3-benzazepine family which was under development for the treatment of Parkinson's disease but was never marketed.[1][2][3] It is a cyclized phenethylamine and catecholamine and is a modified derivative of the monoamine neurotransmitter dopamine.[4] The drug is taken orally.[1]
- None
 | |
| Clinical data | |
|---|---|
| Other names | SKF81297; SKF-81297; SK&F-81297; SK&F-81,297; SK&F81297 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine receptor agonist; Dopamine D1-like receptor agonist; Stimulant; Antiparkinsonian agent |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H16ClNO2 |
| Molar mass | 289.76 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug acts as a selective dopamine D1 and D5 receptor full agonist.[3] In addition, it acts as a partial agonist at dopamine D1–D2 receptor heteromers.[5] It produces a characteristic stimulant-like pattern of effects including anorexia, hyperactivity, and self-administration in animals.[3] This profile is shared with several related drugs such as 6-Br-APB and SKF-82,958,[6] but not with certain other dopamine D1 receptor full agonists such as A-77,636, reflecting functional selectivity of dopamine D1 receptor activation.[7][8][9] The drug also produces pro-motivational effects in animals.[10]
Although it produces stimulant-like effects in animals, SKF-81,297 did not substitute for dextroamphetamine in rodent drug discrimination tests in multiple studies.[11][12] This is in notable contrast to dopamine D2 receptor agonists like quinpirole and RU-24213, which fully substitute for dextroamphetamine in such tests.[13] However, in another study, higher doses of SKF-81,297 were able to partially substitute for dextroamphetamine.[13]
SKF-81,297 readily crosses the blood–brain barrier in rodents and shows substantially greater penetration than the related dopamine D1-like receptor agonist SKF-38,393.[12] Its predicted log P is 2.7.[14]
SKF-81,297 was first described in the scientific literature by 1988.[15] It was developed by GlaxoSmithKline.[1][2] The drug reached the preclinical research stage of development for Parkinson's disease prior to the discontinuation of its development.[1][2] One of the patented uses for SKF-81,297 is as an augmentation agent when combined with an appropriate choice of an antidepressant.[16]